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Abstract
Background: Experimental autoimmune encephalomyelitis (EAE) is an animal model that captures many of the
hallmarks of human multiple sclerosis (MS), including blood–brain barrier (BBB) breakdown, inflammation,
demyelination and axonal destruction. The standard clinical score measurement of disease severity and progression
assesses functional changes in animal mobility; however, it does not offer information regarding the underlying
pathophysiology of the disease in real time. The purpose of this study was to apply a novel optical imaging
technique that offers the advantage of rapid imaging of relevant biomarkers in live animals.
Methods: Advances in non-invasive fluorescence molecular tomographic (FMT) imaging, in combination with a
variety of biological imaging agents, offer a unique, sensitive and quantifiable approach to assessing disease biology
in living animals. Using vascular (AngioSense 750EX) and protease-activatable cathepsin B (Cat B 680 FAST) near
infrared (NIR) fluorescence imaging agents to detect BBB breakdown and inflammation, respectively, we quantified
brain and spinal cord changes in mice with relapsing-remitting PLP139-151-induced EAE and in response to
tolerogenic therapy.
Results: FMT imaging and analysis techniques were carefully characterized and non-invasive imaging results
corroborated by both ex vivo tissue imaging and comparison to clinical score results and histopathological analysis
of CNS tissue. FMT imaging showed clear differences between control and diseased mice, and immune tolerance
induction by antigen-coupled PLGA nanoparticles effectively blocked both disease induction and accumulation of
imaging agents in the brain and spinal cord.
Conclusions: Cat B 680 FAST and AngioSense 750EX offered the combination best able to detect disease in both
the brain and spinal cord, as well as the downregulation of disease by antigen-specific tolerance. Non-invasive
optical tomographic imaging thus offers a unique approach to monitoring neuroinflammatory disease and
therapeutic intervention in living mice with EAE.
Keywords: Experimental autoimmune encephalomyelitis (EAE), Protease, Molecular imaging, Near infrared
fluorescence
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Background
The experimental autoimmune encephalomyelitis (EAE)
model of MS captures many of the hallmarks of the hu-
man disease [1,2]. EAE can be induced in specific strains
of mice by immunization with CNS tissue homogenates,
purified myelin proteins or peptides derived from these
proteins, providing a valuable model for the assessment of
the immune-related cellular and molecular contributors to
disease induction or progression [3,4].
EAE is generally assessed using a subjective clinical
score assessment, which does not provide information
about underlying cellular or molecular processes and does
not always reflect the underlying pathological changes
[5]. Additional information relative to the understanding
of disease can be obtained through the study of excised
CNS tissues, with standard histology approaches [6], novel
approaches in multiplex staining [7], confocal microscopy
[8] and label-free spectroscopy [9]. A variety of clinical
imaging modalities have been applied to EAE studies,
including positron emission tomography (PET), single-
photon emission computed tomography (SPECT) and
magnetic resonance imaging (MRI). PET and SPECT im-
aging, although useful in EAE [10,11], are of limited broad
utility because of the expense of the imaging systems
and the challenges of working with radioactive tracers.
MRI imaging is also expensive and can show a poor
correlation between MRI findings and clinical symptoms
[12], although advances in targeted MRI contrast agents
[13,14] are beginning to provide more useful biological
and immunological information.
Optical imaging is a relatively new modality and offers
the potential advantage of rapid imaging of biological
markers. Approaches with bioluminescence and fluor-
escence in demyelination research have relied on either
transgenic luciferase-expressing mice [15] or systemically
injected fluorescence imaging agents [16], respectively,
relying on 2D surface bioluminescence or epifluorescence
signals. More recent advances in fluorescence molecular
tomography (FMT) offer a simple and inexpensive imaging
option for preclinical research with the benefits of deep
tissue detection and improved accuracy of quantification
[17-19]. Here, for the first time we apply FMT in conjunc-
tion with near infrared (NIR) agents to test the hypothesis
that we can detect demyelinating disease and therapeutic
efficacy in the brain and spinal cord of EAE mice. A variety
of NIR agents were useful in detecting changes associated
with disease, including protease activatable agents to detect
cathepsin and matrix metalloprotease (MMP) activity asso-
ciated with inflammation (Cat B 680 FASTTM, ProSense®
750EX and MMPSense® 750 FAST), enzymatic renin
activity associated with abnormal renin-angiotensin-system
activity in the CNS (ReninSense 680 FASTTM) and vascular
agents designed to detect blood–brain barrier break-
down (AngioSense® 680, AngioSense® 750EX). Imaging
and analysis techniques were carefully characterized
and non-invasive imaging results corroborated by both
ex vivo tissue imaging and comparison to clinical score
results. Cat B 680 FAST and AngioSense 750EX offered
a combination best able to detect disease in the brain
and spinal cord, as well as the downregulation of disease
by antigen-specific tolerance.
Materials and methods
Induction and clinical evaluation of EAE
For the PLP139-151-induced experimental autoimmune
encephalomyelitis experiments, specific pathogen-free
female SJL/J mice (6 to 8 weeks of age) were purchased
from Harlan Laboratories (Indianapolis, IN) and housed
at the Center for Comparative Medicine at Northwestern
University (Chicago, IL) under a controlled environment
(72°F; 12:12-h light–dark cycle) under specific pathogen-
free conditions with water and food provided ad libitum.
All experiments were performed in accordance with North-
western University IACUC guidelines for animal care and
use. Proteolipid protein (PLP)139–151 (HSLGKWLGHPDKF)
and ovalbumin (OVA)323–339 (ISQAVHAAHAEINEAGR)
were purchased from Genemed Synthesis. EAE was elicited
by immunization with 50 μg of PLP139-151 in complete
Freund’s adjuvant (CFA) supplemented with 200 μg
heat-killed M. tuberculosis H37Ra (Difco Laboratories,
Detroit, MI). A volume of 0.1 ml of emulsion was distrib-
uted subcutaneously over three spots on the dorsal flanks
on day 0. Observational clinical scores for each mouse were
recorded daily using a scale of 0–5 as listed below:
Clinical Score of 0: No abnormalities
Clinical Score of 1: Limp tail or hind limb weakness
Clinical Score of 2: Both limp tail and hind limb weakness
Clinical Score of 3: Partial hind limb paralysis
Clinical Score of 4: Total hind limb paralysis
Clinical Score of 5: Moribund
Tolerance induction with Ag-coupled nanoparticles
As previously described [20], 500-nm carboxylated PLGA
microparticles were purchased from Phosphorex, Inc.
(Fall River, MA), and peptide antigens were attached using
ECDI (1-ethyl-3-(3′-dimethylaminopropyl)carbodiimide;
EMD Chemicals Inc., Gibbstown, NJ) with 0.08 mg of
peptide in the presence of 0.32 mg ECDI per 1.0 mg of
PLG nanoparticles. Animals received intravenous injec-
tions of approximately 9 × 109 nanoparticles comprising
10–15 μg of peptide, depending on the peptide sequence
used in the coupling reaction.
Fluorescent agents for the detection of inflammation
Six commercially available imaging agents (PerkinElmer
Inc., Waltham, MA) were used to optimize EAE imaging
and detect therapeutic efficacy (Table 1). AngioSense is
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a vascular imaging agent; ProSense and Cat B detect
regions of increased lysosomal cathepsin activity (ProSense
is a pan cathepsin agent, while Cat B is preferentially
cleaved by cathepsin B); ReninSense FAST is activated
by kidney renin.
In vivo fluorescence imaging
Mice were maintained on a low fluorescence alfalfa-free
diet (Harlan 2019) recommended for fluorescence imaging,
and imaging was performed at the peak of disease (d15).
The mice were injected intravenously with 2× the recom-
mended dose of fluorogenic agents (to facilitate brain bio-
distribution) at d14 and imaged 24 h later (Figure 1). Prior
to the imaging, the animals were anesthetized with an i.p.
injection of ketamine (100 mg/kg) and xylazine (20 mg/kg)
in PBS, and hair from each mouse was removed using
depilatory cream (Nair, Church & Dwight Co., Ewing, NJ).
The cream was applied 2–3 times, for only 4–5 min each
time, to minimize harm to the skin. The animals were then
imaged using the FMT 4000™ fluorescence tomography
in vivo imaging system (PerkinElmer, Hopkinton, MA). For
whole body imaging, the anesthetized mouse was placed in
a prone position on the imaging cassette to capture the
spine or brain of the animal within the imaging scan field.
The imaging cassette was adjusted to the proper depth to
gently restrain each mouse and then inserted into the
heated docking system (regulated at ~37°C) in the FMT
imaging chamber. For imaging the head, the mouse was po-
sitioned prone on a resin block (designed to mimic optical
scattering and absorption properties of the mouse’s body
and minimize imaging artifacts from air-containing spaces
in the head, such as ear canals and sinuses) and posi-
tioned in the imaging cassette. A NIR laser diode was
used to transilluminate (i.e., pass light through the
body of the animal to be collected on the opposite side)
each mouse’s body, with signal detection occurring via
a thermoelectrically cooled CCD camera placed on the
opposite side of the imaged animal. Appropriate op-
tical filters allowed collection of both fluorescence and
excitation data sets, and the multiple source-detector
fluorescence projections were normalized to the paired
collection of laser excitation data. The entire image
acquisition sequence took approximately 6–8 min per
mouse. FMT 4000 epifluorescence imaging was rou-
tinely performed prior to each tomographic imaging
session using built-in LED front illuminators and col-
lection of single camera images.
Animals that were imaged in vivo were then euthanized
by exsanguination following anesthesia. The mice were
transcardially perfused with cold PBS, and the brains and
spinal cords were removed post-mortem then imaged by
epifluorescence imaging using the FMT 4000.
Table 1 Characteristics of fluorescent imaging agents
Agent Description M.W. Peak Ex/Em Biological activity
Cat B 680 FAST Cathepsin-activatable 33 kDa 675/693 Macrophage/microglia
MMPSense 750 FAST Metalloproteinase-activatable 43 kDa 749/775 Macrophage/microglia
ProSense 750 EX Cathepsin-activatable 450 kDa 750/770 Macrophage/microglia
ReninSense 680 FAST Renin-activatable 43 kDa 675/693 T cell RAS activity
AngioSense 680 Vascular agent 250 kDa 680/700 BBB breakdown
AngioSense 750 EX Vascular agent 70 kDa 750/770 BBB breakdown
Figure 1 Experimental autoimmune encephalomyelitis induction and imaging. SJL/J mice were immunized with PLP139-151 in CFA as
described in the Materials and Methods section. Mice were monitored for clinical signs of disease and enrolled for imaging agent injection upon
achieving a score of 2 or 3, and asymptomatic mice were excluded from imaging. Control mice (immunized with CFA only) were injected with
imaging agents on day 14. All mice were imaged 24 h after imaging agent injection. For treatment studies, all mice (including asymptomatic
mice from the positive control group) were injected on day 13 for imaging on day 14. Two separate FMT tomographic scans (head and spine)
were performed, and excised brains and spinal cords were imaged by FMT epifluorescence to confirm in vivo results.
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FMT reconstruction and analysis
The collected fluorescence data sets were reconstructed
by FMT 4000 system software (TruQuantTM, PerkinElmer,
Waltham MA) for the quantification of fluorescence signal
within the head and spine. Three-dimensional regions of
interest (ROI) were drawn to encompass each region, and
a modest threshold was applied identically to all animals
within each agent group in order to minimize background
signal. Briefly, the brain ROI for each mouse was placed as
a 9 × 12 × 6-mm (w× h × d) ellipsoid in the appropriate
head region, and a threshold was applied equal to 30% of
the average maximum fluorescence (in nM) of the control
brain ROIs. For spinal cord ROIs, each was placed as a
6 × 31 × 4-mm rectangular prism with thresholding applied
as 10% of the average maximum fluorescence (nM) of
the control spinal cord ROIs. The total amount of brain
and spinal cord fluorescence (in pmoles) was automatically
calculated relative to internal standards generated with
known concentrations of the appropriate NIR dyes. For
visualization and analysis purposes, TrueQuant software
provided 3D images and tomographic slices.
Statistical analysis
Comparisons of the mean peak disease severity between
any two groups of mice were analyzed by Student’s t test.
P values less than 0.05 were considered significant.
Results
Imaging CNS vascular leak in EAE with AngioSense 750EX
To assess whether mouse EAE can be effectively imaged by
FMT, we used an NIR vascular imaging agent, AngioSense
750EX (AS750), to detect vascular leaks in the blood–brain
barrier associated with CNS disease. On day zero, SJL/J
mice were immunized with PLP139-151 in complete Freund’s
adjuvant (CFA) as described in the Materials and Methods
section. Injection sites (3 per mouse) were placed laterally
on the backs of the mice to avoid interference with spinal
cord imaging. PLP peptide-immunized mice achieved mild
disease (average clinical score of 1.4) with 60% disease
incidence. Mice were injected with 4 nmol of AS750
when disease severity in half of the mice achieved a
clinical score of 2–3 (day 14), and imaging was performed
24 h later to allow optimal accumulation of the agent in
BBB-compromised areas of the CNS.
FMT epifluorescence imaging (Figure 2A) shows that
AS750 accumulated as expected within the immunization
sites in both a representative CFA-immunized control
and a PLP139-151-immunized mouse, revealing vascular leak
within the resulting granulomas. Transillumination scan
fields (required for FMT tomographic imaging) were posi-
tioned based upon the epifluorescence images in order to
capture the head and spinal cord in two separate 2–4-min
scans (Figure 2B). Tomographic fluorescence data sets
were acquired, reconstructed in 3D by the FMT software
and represented as 3D image overlays on the mouse
image. Regions of interest (ROI) were placed to quantify
brain (ellipsoidal ROI) and lumbar/sacral spinal cord
(rectangular prism) fluorescent signal in three dimensions,
and the resulting tomographic fluorescent images are
shown in Figure 2C.
To better reveal the differences in AS750 localization
within the specific anatomical regions in which disease
occurs, appropriate tomographic slices were made
through the ROIs of the spine (2 mm depth) and brain
(3 mm depth). The resulting slice images (Figure 3A)
reveal a dramatic difference between the CFA control and
the EAE mouse by excluding extraneous non-CNS signal.
Quantification of the entire 3D ROI data sets (i.e., all slices
per ROI) from the brain and spine of all of the mice
(Figure 3B) was performed with modest thresholding
applied to minimize background signal in the control
mice (described in Materials and Methods). Quantification
revealed highly significant elevations in fluorescent signal
associated with EAE. Interestingly, although disease
incidence (as defined by clinical score) was 60%, all of
the EAE mice, including those that were asymptomatic
(i.e., no hindlimb weakness or gait abnormalities), showed
elevated brain fluorescence (i.e., fluorescence greater than
control mean + 2 SD), and 60% showed elevated spine
signal. These non-invasive imaging results were confirmed
by ex vivo epifluorescence imaging and quantification of
excised brain and spinal cord tissue (Figure 3C), with both
the images and epifluorescence measurements in strong
agreement with non-invasive in vivo imaging.
Imaging changes in CNS protease activity in EAE mice
Upregulated proteolytic activity is associated with a number
of diseases, including cancer, inflammation, neurodegenera-
tion, cardiovascular disease, arthritis, and diabetes [21-23].
In MS, both matrix metalloproteases (MMP) [24] and
cathepsins [25,26] are expressed in inflammatory cells and
have been implicated as playing a role in BBB breakdown
and/or direct myelin destruction. Even renin, a protease
generally associated with regulation of blood pressure, has
been implicated in the regulation of inflammatory cell in-
flux [27], supporting a proposed role for the tissue-specific
renin-angiotensin system in MS pathogenesis.
We next examined the potential of assessing protease
activity as a biomarker of EAE severity by imaging mice
at peak of acute disease with protease-activatable NIR
fluorescence imaging agents: Cat B 680 FAST (CB680)
for cathepsin B activity, ProSense 750EX (PS750) for
pan-cathepsin activity (Cat B, L, S, K, V), MMPSense 750
FAST (MMP750) for pan-matrix metalloprotease activity
(MMPs 2, 7, 9, 12, 13 and others), and ReninSense 680
FAST (RS680) for renin activity. The average clinical score
of all PLP139-151-immunized mice for this study was 1.45
on day 14, with disease incidence of 53%. Asymptomatic
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mice were excluded from the study, and the overtly
diseased animals showed an average clinical score of 2.75.
Control mice were injected intravenously with agents 14 days
after immunization with CFA; PLP139-151-immunized
mice were injected with agents on the first day that they
achieved a clinical score of 2 or 3 (days 13–14). Mice were
imaged and analyzed as described in the study shown in
Figures 2 and 3, and the data show the fluorescence
(pmol) in brain and spine and the fold change as compared
to control mice (Figure 4A). In addition, isolated brain
and spinal cord tissue fluorescences (counts/energy) were
assessed by epifluorescence imaging (Figure 4B).
CB680 imaging showed statistically significant eleva-
tions in the brains of EAE mice (3.6-fold increase relative
to controls), and this was confirmed in ex vivo tissue
imaging. Interestingly, neither RS680 nor MMP750 showed
significant brain elevations, despite the association of
MMPs and renin in EAE and the similar molecular
weights as compared to CB680. In contrast, RS680
showed statistically significant elevations in the spinal
cord, confirmed by ex vivo tissue assessment. CB680
also showed spinal cord elevation as confirmed both by
ex vivo imaging and histological examination show-
ing activated cathepsin B expression in F4/80+ macro-
phages/microglia in a spinal cord inflammatory lesion
(Figure 4C), but the variability of the in vivo imaging in
this particular study prevented attainment of statistical
significance. One of the most interesting findings was
Figure 3 Quantifying BBB disruption. PLP139-151-immunized mice were injected intravenously with AS750 upon achieving a clinical score of 2
or 3 and imaged by FMT 4000 using tomographic scanning capabilities. CFA control mice were injected 14 days following immunization. (A) NIR
tomographic fluorescent signal in 2–3-mm slices through the spinal cord and brain regions of representative control and diseased mice. (B) NIR
tomographic quantification of the fluorescent signal (mean pmol ± SE) in the brains and spinal cord of all experimental mice. (C) Brains and
spinal cord tissues of the same representative mice shown in A were imaged by epifluorescence on the FMT (left panel). Epifluorescence
quantification (right panel) for tissues from all mice. Study is representative of three separate experiments, #p < 0.05, *p < 0.01, **p < 0.005).
Figure 2 EAE image acquisition and analysis of AS750. (A) Whole-body epifluorescence AS750 signal was acquired to show signal within the
sites of immunization. (B) FMT tomographic scan fields (left panel) show the transillumination scan pattern performed for the spine and head
regions. 3D ROI placement and sizing is shown for the separate head and spine scans (right panel). (C) Total fluorescent signal in 3D throughout
the spine and head regions is shown to reveal the complexity of bodily signal following AS750 injection.
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that the pan-cathepsin imaging agent, PS750, did not
show a signal within the brain and spinal cord despite
its ability to detect cathepsin B in a manner similar to
CB680. As the molecular weight of this agent is ap-
proximately 450,000 Da, it appears that this may have
affected BBB passage.
Imaging therapeutic efficacy of antigen-specific immune
modulation in EAE mice
We have recently shown that intravenous injection of
PLP139-151-coupled polystyrene or biodegradable poly
(lactic-co-glycolic acid) beads (PLP-PSB or PLP-PLGA)
can decrease EAE induction and severity induced by
Figure 4 Imaging protease activity in vivo. PLP139-151-immunized mice were injected intravenously with various protease-activatable NIR
fluorescence imaging agents [CB680 for cathepsin B activity; PS750 for pan-cathepsin activity (Cat B, L, S, K, V); MMP750 for pan-matrix
metalloprotease activity (MMPs 2, 7, 9, 12, 13 and others); and RS680 for renin activity] upon achieving a clinical score of 2 or 3 and imaged by
FMT 4000 using tomographic scanning capabilities. CFA control mice were injected 14 days following immunization. (A) Quantification of in vivo
tomographic fluorescence data sets. (B) Quantification of epifluorescence signal from excised brains and spinal cords. Symbols indicate statistical
significance (#p < 0.05, **p < 0.005). Fold change compared to CFA controls is indicated in parentheses for the in vivo imaged mice. (C) Low and
high power magnifications of cathepsin B expressing macrophages/microglia in a frozen section of an inflammatory lesion in the dorsal sacral
spinal cord of a perfused EAE mouse injected with CB680 24 h previously. Green (anti-F4/80); red (CB680); blue (DAPI).
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PLP139-151 immunization when using either prophylactic or
therapeutic treatment regimens [20]. These particles are
taken up via scavenger receptors on antigen-presenting
cells to induce both pathogenic T cell hyporesponsiveness
(anergy) and increased activity of regulatory T cells. We
assessed the ability of CB680/AS750 imaging to detect
tolerance-induced disease inhibition by treating mice with
either OVA323-339-PLGA (OVA tolerized) or PLP139-151-
PLGA (PLP tolerized) 7 days prior to immunizing mice
with PLP139-151/CFA. The average clinical score of control
OVA-tolerized mice was 2.4 by day 13, with disease inci-
dence over 70% (Figure 5). In contrast, both average clinical
score and disease incidence were significantly decreased in
PLP-tolerized mice (clinical score 0; incidence 0%).
On day 13, all OVA- and PLP-tolerized mice were
injected with a cocktail of CB680 and AS750 and imaged
on day 14 (24 h later). Imaging results focused only on the
signal within the spinal cord and brain regions for control
OVA-tolerized (Figure 6A) and PLP-tolerized (Figure 6B)
mice. Left panels show an overlay of AS750 and CB680
signal within the affected tissues in the living mice, with a
clear difference apparent in the comparison of controls and
tolerized mice. Very little signal is seen in the PLP-tolerized
mice, whereas widespread regions of distinct and coloca-
lized fluorescent signals are seen in the OVA-tolerized
controls. As has been observed in previous studies, the
brain signal in diseased mice tends to be much more
variable than that in the spine regions; only half of the
mice showed high brain signal. The right panels show
the epifluorescence signal in the excised brain and spinal
cord tissue, again represented as a two-color overlay of
the two imaging agents. This ex vivo assessment corre-
lates well with the non-invasive images acquired in the
living mice.
Quantification of the two-channel fluorescent signal
in EAE mice shows excellent detection of therapeutic
efficacy of PLP tolerance induction when examining
the spinal cord region (Figure 7) of the in vivo imaging
data sets (left panels). Brain data, in contrast, showed
the inherent variability of brain disease and a lack of
correlation with clinical score. Thus, although there was a
trend toward a decrease in brain signal with PLP-PLGA
treatment, a much larger study would be required to
assess this. The ex vivo brain and spinal cord tissue im-
aging by epifluorescence (right panels) confirmed in vivo
observations and showed marginal statistical significance
for AS750 brain signal.
Discussion
Rodent models of EAE are used in research and drug
development because of their similar pathology and/or
pathogenesis to human MS and their ease of use and
reproducibility. These models share a number of important
morphologic and immunologic features with human MS,
and they have contributed greatly to the overall knowledge
of immune-mediated myelin destruction. Damage occurs
in three phases; first some abnormal areas of tissue
damage appear in the brain and spinal cord, followed
later by leaks in the blood–brain barrier and then immune
cell infiltration ultimately leading to demyelination [28].
EAE disease assessment relies heavily upon subjective
clinical scoring of symptoms that capture little information
regarding the molecular processes that drive these phases
of disease. More detailed mechanistic information is
typically obtained by histologic analyses of affected brain
and spinal cord tissues.
New vascular and protease-activatable molecular im-
aging agents, as well as current improvements in imaging
methods, provide an opportunity to gather non-invasive
in vivo biological data regarding disease severity, progres-
sion and response to therapy. BBB compromise in EAE is
well characterized [29], and AngioSense, a validated NIR
vascular imaging agent [30,31], offers an opportunity for
in vivo imaging of vascular leak into the CNS. In addition,
as proteases play a central role in cancer and inflammatory
disease processes, we anticipated that protease-activatable
NIR imaging agents [32,33] could serve as a sensitive
means for detecting neuroinflammation in EAE and
changes with therapeutic intervention. Protease-activatable
agents have been used to image protease increases in a
number of disease states, including cancer [34,35], asthma
[36,37], atherosclerosis [38,39] and arthritis [40,41]. How-
ever, it remained to be determined whether this collection
of NIR imaging agents can pass the BBB and effectively
detect disease within the CNS.
Figure 5 Clinical scores and disease incidence for control and
PLP-tolerized mice. Mice were injected with OVA322-339-conjugated
or PLP139-151-conjugated PLGA nanoparticles 7 days prior to
immunization with PLP139-151 in CFA (as described in Materials
and Methods). Mean clinical scores (left panel) were assessed on
days 7 through 15 following immunization, and disease incidence
(right panel) was determined based on mice with a score of at least 1.
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For the first time, we show the benefit of fluorescence
molecular tomographic imaging in a mouse model of MS
and demonstrate that tomography can not only provide
images reflecting the disease severity, but also provide multi-
plex quantitative measurements (Figures 2, 3, 5 and 6). The
first challenge in establishing a method for non-invasive
EAE imaging of the brain and spinal cord was to deter-
mine whether our multiple potential agents, ranging in
size from 33–450 kDa, could penetrate the BBB of mice.
A number of preliminary studies with larger molecular
Figure 6 NIR tomographic multiplex imaging AS750 and CB680 in control and PLP-tolerized mice. (A) Tomographic images of vascular
leak and cathepsin B activity in brain and lumbar/sacral spinal cord of control OVA-tolerized mice (left panel). Extraneous non-CNS signal was
excluded for clarity. Right panel shows CB680/AS750 signal from excised brain and spinal cord tissue. (B) Tomographic images of vascular leak
and cathepsin B activity in brain and lumbar/sacral spinal cord of control PLP-tolerized mice (left panel). Extraneous non-CNS signal was excluded
for clarity. Right panel shows CB680/AS750 signal from excised brain and spinal cord tissue. Tomographic images from A and B are represented
as fluorescence isosurfaces showing signal ≥65 nM (CB680 brain), ≥200 nM (AS7750 brain) and ≥100 nM (CB680/AS750 spine). Epifluorescence
images are represented with the same monochrome color scales for both control and tolerized mouse tissues.
Figure 7 Quantifying PLP-specific tolerance induction in EAE. Fluorescence tomography and tissue epifluorescence were quantified for
control and PLP-tolerized mice from the study represented in Figures 4 and 5. The left panel shows the quantification of in vivo tomographic
fluorescence data sets. The right panel shows the quantification of epifluorescence signal from excised brains and spinal cords. Symbols indicate
statistical significance (#p < 0.05, ***p < 0.0001).
Eaton et al. Journal of Neuroinflammation 2013, 10:138 Page 8 of 11
http://www.jneuroinflammation.com/content/10/1/138
weight AS750 (250 kDa) and activatable PS680 (450 kDa)
revealed superior CNS accumulation by the somewhat
smaller AS750 (data not shown), consistent with our
findings in these studies. This led us to perform much
of our early method validation with AS750, defining
ROI shapes and sizes as well as optimal fluorescence
thresholding approaches that yielded the technique de-
scribed in Materials and Methods. All of our data to
date have revealed considerable variability in brain disease
(as also shown in the studies in Figures 4 and 6) and have
further suggested that brain signal decreases dramatically
in severely affected animals (clinical score of 4). Interest-
ingly, PLP peptide-immunized animals with clinical scores
of 0 or 1 often show as much brain fluorescence as mice
with clinical scores of 2 or 3. This suggests that there can
be some form of active disease occurring even in mice
with no clinical symptoms, a finding that is not surprising
as EAE clinical scores are mostly an assessment of spinal
cord damage. Spine signal, on the other hand, generally
correlates reasonably well with the clinical score but with
more variability in mice with clinical scores of 4. Despite
careful care of these animals, some of this decline in ser-
iously diseased animals may be due to overall physiologic
changes caused by dehydration and decreased circulation
in these animals.
Optical tomographic imaging using NIR imaging agents
in EAE has the potential for use in drug discovery research
by virtue of deep tissue penetration, quantitative readout
(pmol rather than light intensity) and the pairing with NIR
imaging agents that detect the cellular participants in
the underlying disease pathology. For the past 25 years,
the Miller laboratory has explored specific T cell tolerance,
induced by antigen-coupled splenocytes, as a means to both
treat disease [42-45] and probe mechanisms of immu-
nopathogenesis [46,47]. Recent advances in techniques
for inducing T cell tolerance to specific neuroantigen
epitopes have yielded an approach using antigen-coupled
biodegradable PLGA nanoparticles to probe mechanisms
of immune tolerance induction [20]. We applied our FMT
imaging techniques with two of the best NIR agents iden-
tified from our validation studies, and were able to detect
and quantify decreases in spinal cord vascular leak and ca-
thepsin B activity in agreement with the effects on clinical
scores (Figures 4, 5, and 6). Brain signal was variable, and
half of the OVA-tolerized control mice showed little brain
fluorescent signal with either agent. This highlights the
variability of brain disease, but it also shows that vascular
leak changes accompany cathepsin B changes as would
be expected given that BBB compromise generally accom-
panies neuroinflammation. We were also able to confirm
abnormal renin activity in EAE, in agreement with reports
that a CNS renin-angiotensin system may be involved in
the regulation of the disease [27]. Unfortunately, a similar
agent for the detection of matrix metalloprotease activity
(MMP750) was unable to detect changes in EAE despite
the presence of MMP-secreting inflammatory cells. It is
unclear whether unknown physical/chemical properties of
this agent limited its CNS penetration or activity in vivo.
Future studies will assess these agents, and additional NIR
imaging agents, for their utility to detect disease as well as
their sensitivity in detecting very early, subclinical disease.
Our studies have built upon advances in imaging tech-
nology to establish non-invasive optical tomographic
imaging as a robust and accurate means of assessing BBB
compromise and neuroinflammation in EAE in vivo.
This technology offers a powerful tool for both basic
neuroinflammation research and drug discovery and devel-
opment by enabling the non-invasive monitoring of cellular
processes that also drive human MS pathology. FMT
thus should provide a rapid means for assessing and
characterizing therapeutics for clinical evaluation.
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